Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
Bioaffinity Technologies, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 7, 2026. The filing announces the issuance of a press release containing financial information for the second quarter ended June 30, 2026. The company is listed on The Nasdaq Stock Market LLC under the symbols BIAF (Common Stock) and BIAFW (Tradeable Warrants).
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific financial data. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity for the period ended June 30, 2026.
Material Changes
No material changes versus the prior comparable period are detailed in this specific document. The filing explicitly states that the financial information is contained within the attached press release, which is not included in the input text.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings. No specific guidance, management commentary, risks, or contingencies are described in the text of this 8-K.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release) for actual Q2 2026 financial figures, as they are absent from the 8-K body.
- Verify the company's status as an emerging growth company (indicated as "Yes" in the filing).
- Confirm the trading status of Common Stock (BIAF) and Warrants (BIAFW) on The Nasdaq Stock Market LLC.
- Note that the financial data in the referenced press release is not subject to the liabilities of Section 18 of the Exchange Act.